Image

Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2

Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2

Not Recruiting
85 years and younger
All
Phase N/A

Powered by AI

Overview

Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an autosomal recessive disease caused by mutations in the autoimmune regulator (AIRE) gene, characterized by the clinical triad of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenal insufficiency. CMC can be complicated by systemic candidiasis or oral squamous cell carcinomas (SCCs) and may lead to death. The role of chronic Candida infection in the etiopathogenesis of oral SCC is unclear. Long term use of fluconazole lead to emergence of C. albicans strains with azoles decreased susceptibility. CMC is associated with an impaired Th17 cell response, however, it remains unclear whether decreased serum IL-17 and IL-22 levels are related to a defect in cytokine production or to neutralizing autoantibodies resulting from mutations in the AIRE gene

Eligibility

Inclusion Criteria:

  1. For both of groups, inclusion criteria are :
    • children aged 0 to 17 years old with the consent of both parents, and men and women between the ages of 18 and 85.
    • a reasonable delay of 2 weeks after the resolution of an intercurrent infectious episode is to be observed.
    • assent of the patient after information adapted to his age and his degree of understanding.
    • informed, express and written consent of the patient or of each of the holders of parental authority.
  2. Inclusion criteria specific to group 1: Patients with a APS type 1 whose molecular

    diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.

  3. Inclusion criteria specific to group 2 : Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.

Exclusion Criteria:

  • impossibility to receive informed information for adults, or impossibility to receive enlightened information for the holders of parental authority if minor subject
  • inability to participate in the entire study, refusal to sign the consent.
  • people in an emergency situation.
  • persons deprived of their liberty.
  • pregnant or lactating woman (pregnant women will be offered to participate in the study after delivery).

Study details
    Polyendocrinopathies
    Autoimmune

NCT03800056

University Hospital, Lille

13 May 2026

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.